The Promise of Tumor Mutation Burden and Microenvironment as Biomarkers in Glioma Treatment

Gliomas, particularly high-grade gliomas like glioblastomas, represent some of the most formidable challenges in oncology. These brain tumors are notorious for their resistance to conventional therapies, including surgery, chemotherapy, and radiation. The recent systematic review and meta-analysis protocol offers a promising direction by focusing on Tumor Mutation Burden (TMB) and Tumor Microenvironment (TME) as potential biomarkers for treatment outcomes and prognosis in gliomas.

Tumor Mutation Burden (TMB) refers to the number of mutations per mega base of DNA within a tumor. It has emerged as a significant biomarker in various cancers, predicting response to Immune Checkpoint Inhibitors (ICIs). The protocol highlights that hyper mutated gliomas, characterized by high TMB, may produce numerous neoantigens. These neoantigens can be recognized by CD8+ T lymphocytes, potentially rendering the tumor more susceptible to immunotherapy [1,2].

In gliomas, TMB can vary significantly, with some tumors exhibiting hyper mutation pathways such as Mismatch Repair Deficiency (MMR) and those induced by Temozolomide (TMZ) resistance [1]. The study suggests that gliomas with high TMB could present better responses to ICIs, offering a new therapeutic avenue for patients who previously had limited options [3,4]. This insight is crucial, given the dismal prognosis of glioblastomas with median survival often less than a year [2].

The Tumor Microenvironment (TME) encompasses various cell types, including stromal cells, immune cells, and extracellular matrix components, which interact dynamically with tumor cells. The review underscores the role of TME in influencing tumor growth, invasion, and resistance to treatment [5]. Tumor-Associated Macrophages (TAMs) within the TME can either promote or inhibit tumor progression, depending on their polarization states [5].

Understanding the TME's complexity is vital for developing effective treatments. By targeting the TME, therapies could potentially disrupt the supportive niche that tumors rely on, enhancing the efficacy of existing treatments [6]. This approach aligns with the concept of creating an immunogenic TME that boosts immune response and improves drug delivery [7,8].

The integration of TMB and TME as biomarkers in clinical practice could revolutionize the treatment paradigm for gliomas. By providing a more personalized treatment approach, these biomarkers can help oncologists tailor therapies to individual patients' tumor profiles [1]. For instance, patients with high TMB gliomas might be prioritized for immunotherapy, while those with specific TME characteristics could benefit from targeted therapies that modify the tumor microenvironment [2,4].

Moreover, the systematic review protocol by Kyaruzi, et al. [3] advocates for comprehensive genomic and immune profiling of gliomas. This includes evaluating neoantigen expression, mutation pathways, and immune cell infiltration. Such detailed profiling could lead to more accurate predictions of treatment responses and better prognostic assessments [5].

While the potential of TMB and TME as biomarkers is promising, several challenges remain. The heterogeneity of gliomas, both intertumoral and intratumoral, complicates the identification of consistent biomarkers [6]. Additionally, the mechanisms underlying the interaction between TMB, TME, and therapeutic response need further elucidation [8,9].

Future research should focus on large-scale clinical trials to validate these biomarkers and refine their use in clinical settings [3]. Developing robust and standardized methods for measuring TMB and assessing TME will be critical [4]. Furthermore, exploring the synergy between TMB, TME, and other emerging biomarkers could open new avenues for combination therapies, ultimately improving outcomes for glioma patients [7].

The insights provided by the systematic review and meta-analysis protocol on TMB and TME as biomarkers herald a new era in glioma treatment. By leveraging these biomarkers, clinicians can move towards more personalized and effective treatment strategies, offering hope to patients battling these aggressive tumors [2]. Continued research and clinical validation will be essential to fully realize the potential of TMB and TME in transforming glioma therapy [9].

1. Ahmad H, Fadul CE, Schiff D, Purow B. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. Neurooncol Pract. 2019 Dec;6(6):424-427. doi: 10.1093/nop/npz016. Epub 2019 Apr 7. PMID: 31832212; PMCID: PMC6899050.
2. Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, Ranjan A, Kim O, Wei JS, Chou HC, Wen X, Sindiri S, Song YK, Xi L, Kaplan RN, Armstrong TS, Gilbert MR, Aldape K, Khan J, Wu J. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers (Basel). 2021 Dec 3;13(23):6092. doi: 10.3390/cancers13236092. PMID: 34885201; PMCID: PMC8657099.
3. Kang K, Xie F, Wu Y, Wang Z, Wang L, Long J, Lian X, Zhang F. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Int Immunopharmacol. 2021 Jul;96:107610. doi: 10.1016/j.intimp.2021.107610. Epub 2021 Apr 10. PMID: 33848908.
4. Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021 Mar 1;27(5):1236-1241. doi: 10.1158/1078-0432.CCR-20-3054. Epub 2020 Nov 16. PMID: 33199494; PMCID: PMC9912042.
5. Alghamri MS, Thalla R, Avvari RP, Dabaja A, Taher A, Zhao L, Ulintz PJ, Castro MG, Lowenstein PR. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi: 10.1093/noajnl/vdaa042. PMID: 32642696; PMCID: PMC7212865.
6. Su J, Long W, Ma Q, Xiao K, Li Y, Xiao Q, Peng G, Yuan J, Liu Q. Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Front Genet. 2019 Nov 15;10:1143. doi: 10.3389/fgene.2019.01143. PMID: 31803233; PMCID: PMC6872675.
7. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH, Moreno CS, Brat DJ. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012 May;180(5):2108-19. doi: 10.1016/j.ajpath.2012.01.040. Epub 2012 Mar 20. PMID: 22440258; PMCID: PMC3354586.
8. Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med. 2018 Aug;12(4):426-439. doi: 10.1007/s11684-018-0663-7. Epub 2018 Aug 10. PMID: 30097962.
9. Wang L, Ge J, Lan Y, Shi Y, Luo Y, Tan Y, Liang M, Deng S, Zhang X, Wang W, Tan Y, Xu Y, Luo T. Tumor mutational burden is associated with poor outcomes in diffuse glioma. BMC Cancer. 2020 Mar 12;20(1):213. doi: 10.1186/s12885-020-6658-1. PMID: 32164609; PMCID: PMC7069200.